Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products an...
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02472665
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
🇪🇸Hospital Sant Joan de Déu Barcelona, Esplugues De Llobregat, Barcelona, Spain
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 49
- Registration Number
- NCT02413580
- Locations
- 🇦🇷
Hospital Italiano, Buenos Aires, Argentina
🇦🇷Hospital General de Agudos Dr. J. M., Buenos Aires, Argentina
🇭🇺Jahn Ferenc Del-Pesti Korhaz, Budapest, Hungary
A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02282527
- Locations
- 🇺🇸
University of Miami - Miller School of Medicine, Miami, Florida, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
🇺🇸PMG Research of Wilmington, Wilmington, North Carolina, United States
Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
- Conditions
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02281500
- Locations
- 🇺🇸
Northshore Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇮🇹Agenzia per l'Emofilia Centro di Riferimento Regionale per le Coaugulopatie Congenite A.O. di Carreggi, Firenze, Italy
🇱🇧Hôtel-Dieu de France Hospital, Beirut, Lebanon
An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02139657
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 76
- Registration Number
- NCT02093221
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Endocrinology Associates Inc, Columbus, Ohio, United States
Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 425
- Registration Number
- NCT02037555
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Summa Health Hospital, Akron, Ohio, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 345
- Registration Number
- NCT01983241
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇷🇴Clinic Dr.G Curteanu Oradea, Oradea, Romania
🇪🇪Tartu University Hospital, Tartu, Estonia
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01684410
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸UNC at Chapel Hill, Chapel Hill, North Carolina, United States
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01465958
- Locations
- 🇺🇸
IMMUNOe International Research Centers, Centennial, Colorado, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Joe DiMaggio Children's Hospital, Hollywood, Florida, United States